Business Wire

Aragen (Formerly GVK BIO) to Partner With Global Biopharma With a Renewed Brand Promise

2.6.2021 14:25:00 EEST | Business Wire | Press release

Share

Aragen Life Sciences (Aragen), formerly known as GVK Biosciences and a leading contract research, development and manufacturing organization, officially marked its transition to a new brand identity. With a legacy of over 20 years of partnering with innovator life sciences companies around the world, Aragen is poised for growth in the outsourced discovery, development, and manufacturing services sector across both large and small molecule platforms.

The global Pharmaceutical CDMO market, valued USD 160.12 billion in 2020, is expected to reach USD 236.61 billion by 2026, registering a CAGR of 6.5%, during the period of forecast (2021-2026), as per a report by Mordor Intelligence. India is seen as a prime location for the CDMO market, and Aragen has demonstrated strong organic growth on the back of deep domain expertise, strong global delivery capabilities, and partnerships with global biopharmaceutical and biotech clients.

Coinciding with its 20 year history and an incoming global investor, Goldman Sachs, Aragen unfolded the new brand. Manni Kantipudi, CEO of Aragen, said, “With an aspiration to be a partner of choice to the life sciences industry, we started humbly 20 years ago. With strategic partnerships and investments over the years, a new investor in the company, and a renewed focus on our customers and solutions, we are ready to take the next leap. Our brand promise of ‘Together Ahead’ and our purpose ‘In every molecule is the possibility for better health’ reflect what Aragen does best – work with our partners and make them successful in the race for better health.”

Elaborating on the new visual brand identity and brand promise, Ramesh Subramanian, Chief Commercial Officer, said, “Our new mark embodies our brand promise, Together Ahead. The seamless coming together of two forms and their collaborative movement, represent our partnerships that enable infinite possibilities for better health. Our symbol which we call ‘AURA’ embodies our distinctive personality — Ambitious, Understated, Resilient and Agile. Aragen’s brand colors are loaded with symbolism and meaning. From the deep blue colour that conveys the possibilities of science, strength and resilience, the transition is made to vibrant orange which symbolizes life, better health, as well as ambition and energy.”

“With this renewed energy and focus, the 3,100+ strong employee base of Aragen, spread across 7 sites in India and overseas, with a pool of over 400 PhDs, is standing ready to continue to serve our existing and new customers in this market.” said Chief Operating Officer, Sudhir Singh.

About Aragen Life Sciences

Aragen Life Sciences Pvt Ltd (Aragen) is a global leader in providing discovery, development and manufacturing solutions for life sciences firms. With a team of over 3100 professionals, and through a network of sites around the world, we offer a seamless, integrated platform to advance customer programs from discovery through commercialization for both small molecules and biologics. Established in 2001, Aragen now serves over 450 customers worldwide across multiple modalities and therapeutic areas.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aragen Life Sciences: Sarat Patanaik, +91 95732 80064, sarat.patanaik@aragen.com
MediaMedic Communications Pvt. Ltd.: Bhavna Pathak, +918830654608, info@mediamedichealth.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 11:00:00 EET | Press release

Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe a chance to catch up, and Plural believes the continent has the founders, research and momentum to build many more global companies of its own. Global companies, built from Europe When Plural launched in 2022, frontier founders working on defence, energy, space and AI infrastructure in Europe struggled to raise capital. Plural’s partners backed startups in these sectors early, and Plu

SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 10:36:00 EET | Press release

SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the future economy. “Digital inclusion depends on more than reaching remote locations. It requires partners that can translate commitments into connectivity that communities can

Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 10:00:00 EET | Press release

Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors faced significant delays in accessing liquidity data and relied on daily calls with bank treasurers, according to the European Banking Authority. Banks and supervisors share the co

Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 09:06:00 EET | Press release

On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the hands of children. Hayley van Loon, CEO of Crime Stoppers International, said: “It’s just a vape. It’s just a pouch. That is exactly what the criminals selling them want you to think. Nobody knows what’s in these products. They’re made in illegal factories with no safety standards and sold to anyone, including

Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 09:00:00 EET | Press release

Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: "The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets. Europe is producing a growing number of world-class life sciences companies, and we believ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye